Загрузка компании
Keep exploring
The themes Astrazeneca is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Drug Manufacturers General
Graded A or B and worth $2B or more: A first, then the largest.
LLYELI Lilly And Company1,36T $A+
JNJJohnson & Johnson688,6B $A+
MRKMerck & Co., Inc.364,3B $A
NVSNovartis AG306,3B $A
AMGNAmgen Inc.251,9B $A+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 окт. 2026 г.CBGraded C, now B
MCKMckesson Corporation4 нояб. 2026 г.BAGraded B, now A
CVSCVS Health Corp4 нояб. 2026 г.BAGraded B, now A
EWEdwards Lifesciences Corporation4 нояб. 2026 г.BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 окт. 2026 г.CAGraded C, now A
На чём зарабатывает
- Sales of prescription medicines
- Revenue from medicine partnerships
Конкурирует с
Что продаёт6
Tagrisso
A prescription medicine for certain lung cancers with changes in the epidermal growth factor receptor gene.
Imfinzi
An immune-system treatment used for several cancers, including lung, bladder, liver and stomach cancers.
Farxiga/Forxiga
A tablet used for type 2 diabetes, heart failure and chronic kidney disease.
Показать ещё 3
Ultomiris
A long-acting medicine for rare diseases in which the immune system damages blood cells or other tissues.
Fasenra
An injected medicine for severe asthma and certain other conditions involving high levels of eosinophils, a type of white blood cell.
Enhertu
A targeted cancer medicine for cancers with high or altered levels of human epidermal growth factor receptor 2.
Кто покупает3
- Patients receive the medicines, usually after a clinician prescribes them.
- Hospitals, clinics and pharmacies purchase or dispense medicines for patients.
- Government health systems and private insurers may pay for or reimburse medicines.
На чём держится и что может это сломать
От чего зависит бизнес
- 1Sales of many medicines depend on patents and other protections that limit competing generic or biosimilar versions.
- 2Some medicines are developed or commercialised with partners, so their sales and revenue depend partly on those arrangements.
- 3Sales in China are affected by government volume-based purchasing and reimbursement decisions.
Что может пойти не так
- 1Generic competition can reduce sales when patents expire or competitors enter early; the company reported generic entry affecting Farxiga and Brilinta.
- 2Clinical trials can fail to show that a medicine works, as occurred in the Wainua heart-disease trial discussed on the latest earnings call.
- 3Government purchasing and reimbursement rules, including China’s volume-based procurement, can affect medicine prices and sales.
Полная финансовая отчётность →
О компании Astrazeneca plc
AstraZeneca develops, makes and sells prescription medicines. Its medicines treat several types of cancer, heart and kidney conditions, breathing and immune disorders, and rare diseases. It also works with other drug companies to develop and sell some medicines, sharing revenue from those partnerships.
- Штаб-квартира
- Cambridge, England, United Kingdom
- Год основания
- 1992
- Торгуется на
- New York Stock Exchange
- Конец финансового года
- December 31
Построено по собственной отчётности Astrazeneca plc, поданной в Комиссию по ценным бумагам и биржам США (SEC). Цифры — как отчиталась компания, история на акцию пересчитана на сегодняшнюю базу. Это описание бизнеса — не инвестиционная рекомендация и не совет что-либо покупать или продавать.